---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025433"
form_type: "8-K"
ticker: "SONM"
cik: "0001178697"
company_name: "DNA X, Inc."
filed_at: "2026-05-27T20:35:28+00:00"
generated_at: "2026-05-27T20:38:19.788608+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# DNA X receives Nasdaq delisting notice; issues $3.05M convertible note to insider

## Summary
- Nasdaq delisting notice due to stockholders' deficit of $983,000 as of March 31, 2026; hearing requested.
- Issued $3,052,788 convertible note to DNA Holdings Venture, Inc. at 10% interest, maturing Dec 31, 2026.
- Note convertible into common at $6.00/share, subject to stockholder approval; proceeds for working capital.
- Concurrently terminated a 'Put Option' under a prior Membership Interest Purchase Agreement.
- Unregistered sale under Section 4(a)(2) and Rule 506(b); Purchaser is an accredited investor.

## SEC filing metadata
- accession: 0001493152-26-025433
- form_type: 8-K
- ticker: SONM
- cik: 0001178697
- company_name: DNA X, Inc.
- filed_at: 2026-05-27T20:35:28+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.03, 3.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/0001493152-26-025433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025433
- JSON: https://secwatch.observer/filing/0001493152-26-025433.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025433.txt

## Source-grounded claims
- claim_id: 53a6353803e5f7b4241632d59cdd853f2db72f6a
  claim: DNA X, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/0001493152-26-025433-index.htm
- claim_id: 685ca6783ee7bd2ae6cbff72020573d224377166
  claim: DNA X, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178697/000149315226025433/0001493152-26-025433-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.